Half of men age 51 to 60 develop pathological benign prostatic hyperplasia (BPH), and that stat increases to 80-90% for men in their 70s and 80s.
Now, at 16 sites across the continent, high-velocity waterjet technology is being used to resect and remove prostate tissue. One of those sites is the result of teamwork among urologists Andrew Trainer, MD, Andrew Arther, MD, the research group at Adult Pediatric Urology & Urogynecology, PC, and CHI Health Creighton University Medical Center - Bergan Mercy.
The Investigational Device Exemption (IDE) study, WATER II, focuses on the safety and effectiveness of treating large (80-150 g) prostates with Aquablation – water ablation therapy. Twelve males with benign prostatic hyperplasia were treated at CUMC - Bergan Mercy and will be followed for up to 12 months.
The previous study, WATER, in which smaller prostates (30-80 g) were studied (203 participants total, 4 at CUMC - Bergan Mercy) recently released its initial findings.
A summary of the reported findings in the WATER study comparing Aquablation to TURP includes:
- Significantly improved BPH symptoms in both treatment groups as measured by the International Prostate Symptom Score (IPSS) at six months with 100 percent of Aquablation patients improving from baseline
- Superiority in IPSS storage symptom sub-scores (p<0.05)
- Superiority in IPSS improvement with Aquablation in men with prostate volume greater than 50 ml as compared to TURP (p<0.01)
- Superiority in peak urinary flow rates (Qmax) at six months
- A significantly lower rate (4 to 1 ratio, p<0.001) of sexual side effects in Aquablation compared to TURP at three months
- Superiority in ejaculatory function (MSHQ-EjD) and incontinence scores (ISI) at three months